How I Practice: Treatment Landscape for mUC
Activity Post-Survey & Application for Credit

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 100% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements.

There is no fee to participate in this activity.

Question Title

* 1. What are your specialty & credentials?

Medical Oncologist (MD/DO)

Surgical Oncologist (MD/DO)

Radiologist (MD/DO)

Hematologist/Oncologist (MD/DO)

Other MD/DO

Trainee/Fellow

Nurse

Pharmacist

Other (please specify)

Question Title

* 2. What is your community of practice?

Academic

Community

Industry

Other (please specify)

Question Title

* 3. What was the most common ≥ grade 3 TRAE associated with enfortumab-vedotin and pembrolizumab in EV-302/ KEYNOTE-A39?

Anemia

Hyperglycemia

Peripheral neuropathy

Skin reactions

Question Title

* 4. In JAVELIN Bladder 100 trial, what was the OS rate at 1 year for patients treated with avelumab maintenance therapy?

51%

61%

71%

81%

Question Title

* 5. A 72-year-old man with mUC is found to have progressive disease on restaging scans 10 months after receiving 1L gemcitabine and cisplatin. Which of the following is the preferred NCCN 2L treatment for this patient?

Gemcitabine

Paclitaxel

Pembrolizumab

Docetaxel

Question Title

* 6. In THOR, cohort 1, what was the mPFS for patients treated with erdafitinib?

5.6 months

7.6 months

9.6 months

11.6 months

EVALUATION FORM

Question Title

* 7. Upon completion of this activity, I am able to:

	Strongly agree	Agree	Disagree	Strongly disagree
DESCRIBE efficacy data regarding ICIs and other approved drug classes, including the use of maintenance therapy in mUC.	DESCRIBE efficacy data regarding ICIs and other approved drug classes, including the use of maintenance therapy in mUC. Strongly agree	DESCRIBE efficacy data regarding ICIs and other approved drug classes, including the use of maintenance therapy in mUC. Agree	DESCRIBE efficacy data regarding ICIs and other approved drug classes, including the use of maintenance therapy in mUC. Disagree	DESCRIBE efficacy data regarding ICIs and other approved drug classes, including the use of maintenance therapy in mUC. Strongly disagree
SELECT appropriate treatment based on the latest recommendations from the National Comprehensive Cancer Network’s preferred treatment regimens for mUC.	SELECT appropriate treatment based on the latest recommendations from the National Comprehensive Cancer Network’s preferred treatment regimens for mUC. Strongly agree	SELECT appropriate treatment based on the latest recommendations from the National Comprehensive Cancer Network’s preferred treatment regimens for mUC. Agree	SELECT appropriate treatment based on the latest recommendations from the National Comprehensive Cancer Network’s preferred treatment regimens for mUC. Disagree	SELECT appropriate treatment based on the latest recommendations from the National Comprehensive Cancer Network’s preferred treatment regimens for mUC. Strongly disagree

Question Title

* 8. Please indicate the extent of your agreement with the following statements:

	Strongly agree	Agree	Disagree	Strongly disagree
The faculty for this activity were effective	The faculty for this activity were effective Strongly agree	The faculty for this activity were effective Agree	The faculty for this activity were effective Disagree	The faculty for this activity were effective Strongly disagree

Question Title

* 9. Overall, was this activity fair, balanced and free from commercial bias?

Yes

Question Title

* 10. If no, please explain:

Question Title

* 11. Of the patients with bladder cancer you will see in the next month, about how many will benefit from the information you learned today?

1 to 10

11 to 25

26 to 50

I am not directly involved in patient care

Question Title

* 12. Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):

Expanded use of novel therapies and appropriate uses in mUC

Application of cutting-edge science in this therapeutic area

Appropriate sequencing of therapeutics

Monitoring and mitigation of TRAEs

Implementation of best practices of my colleagues and leaders

I do not plan on making changes to my practice at this time

Other (explain)

Question Title

* 13. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

Lack of knowledge regarding treatment options (patient-related)

Patient adherence/resistance to new therapeutics and/or clinical trial enrollment (patient-related barrier)

Limited knowledge regarding new therapeutics for mUC (provider-level barrier)

Lack of time resources to consider change (practice-related barrier)

Inadequate support staff for pt education/insurance/billing/administrative issues (practice-level barrier)

Insurance reimbursement or legal issues (systems-related barrier)

Lack of access to novel therapeutics due to regulatory approvals/insurance coverage (systems-related barrier)

Other (please specify)

Question Title

* 14. For purposes of certification, please complete the following information. Please note that we will not forward or sell your contact information.

First Name *

Last Name *

Degree/Credentials:

City

State/Province

ZIP/Postal Code *

Country

Email Address (required to receive credit) *

Question Title

* 15. I certify that I have participated in the continuing education activity entitled, "What Now, What Next? Appropriate Management for mUC | How I Practice: Treatment Landscape for mUC" and claim 0.5 AMA PRA Category 1 Credit^TM.

Yes

Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate.

For additional information about the accreditation of this activity, please visit https://www.partnersed.com

How I Practice: Treatment Landscape for mUC*Activity Post-Survey & Application for Credit*

Question Title

* 1. What are your specialty & credentials?

Question Title

* 2. What is your community of practice?

Question Title

* 3. What was the most common ≥ grade 3 TRAE associated with enfortumab-vedotin and pembrolizumab in EV-302/ KEYNOTE-A39?

Question Title

* 4. In JAVELIN Bladder 100 trial, what was the OS rate at 1 year for patients treated with avelumab maintenance therapy?

Question Title

* 5. A 72-year-old man with mUC is found to have progressive disease on restaging scans 10 months after receiving 1L gemcitabine and cisplatin. Which of the following is the preferred NCCN 2L treatment for this patient?

Question Title

* 6. In THOR, cohort 1, what was the mPFS for patients treated with erdafitinib?

Question Title

* 7. Upon completion of this activity, I am able to:

Question Title

* 8. Please indicate the extent of your agreement with the following statements:

Question Title

* 9. Overall, was this activity fair, balanced and free from commercial bias?

Question Title

* 10. If no, please explain:

Question Title

* 11. Of the patients with bladder cancer you will see in the next month, about how many will benefit from the information you learned today?

Question Title

* 12. Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):

Question Title

* 13. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

Question Title

* 14. For purposes of certification, please complete the following information. *Please note that we will not forward or sell your contact information.*

Question Title

* 15. I certify that I have participated in the continuing education activity entitled, "What Now, What Next? Appropriate Management for mUC | How I Practice: Treatment Landscape for mUC" and claim 0.5 AMA PRA Category 1 CreditTM.

How I Practice: Treatment Landscape for mUC
Activity Post-Survey & Application for Credit

* 14. For purposes of certification, please complete the following information. Please note that we will not forward or sell your contact information.

* 15. I certify that I have participated in the continuing education activity entitled, "What Now, What Next? Appropriate Management for mUC | How I Practice: Treatment Landscape for mUC" and claim 0.5 AMA PRA Category 1 Credit^TM.